A film based on the true story of a leukemia patient smuggling Indian generics has led Beijing to reiterate its intention to cut cancer drug prices.
Boehringer Ingelheim is expanding the $77 million contract biologics plant it opened last year in Shanghai.
Sanofi launches a big data-focused global R&D hub in China; Takeda looks to sell its old HQ for $542 million; I-Mab gets $220 million in series C.
After opening its new global headquarters in Tokyo, Takeda is seeking buyers for its old headquarters in Osaka to help fund its Shire takeover.
The FDA has issued a warning letter for a Sichuan Friendly Pharmaceutical plant at Neijiang, Sichuan.
Foshan Jinxiong Technology has been on an import alert list since February, banning all of its products from entering the U.S.
Inovio's South Korean partner GeneOne plans to start a phase 1/2 study in South Korea in the third quarter.
Biogen will pay about $700 million to boost its stake in Samsung Bioepis to 49.9%. It currently owns 5.4% of the biosimilars joint venture.
Takeda investors worry about Shire's hemophilia products; Biocon's biosimilars plant clears the FDA; C-Bridge Capital invests $35 million in Nuance.
A Chinese API maker that was put on the FDA’s import alert list in March has now been given an FDA warning letter.